Key result
Novel therapeutic strategies, including renal sympathetic denervation and sacubitril/valsartan, offer promising approaches for achieving optimal blood pressure control in patients with resistant hypertension.
Why the study?
Despite combination treatment with multiple antihypertensive drugs, a group of patients with resistant hypertension remains uncontrolled, emphasizing the need for new therapies.
This review emphasizes the importance of overcoming therapeutic inertia and highlights renal sympathetic denervation as a promising interventional strategy for patients with true resistant hypertension.
Does not yet support routine adoption; leaves open the need for dedicated RCTs in resistant hypertension.
Treatment-resistant hypertension, or resistant hypertension (RH), is defined as arterial hypertension (AH) despite treatment with three properly dosed antihypertensive drugs, at least one of which is a diuretic. Resistant hypertension is associated with an increased incidence of adverse cardiovascular events, renal impairment, and increased mortality. The main treatment of patients with RH is based on maximizing doses of antihypertensive drugs from different groups and adding drugs with complementary mechanisms of action. Despite the combination treatment involving multiple antihypertensive drugs, a small but significant group of patients remains with uncontrolled hypertension, emphasizing the need to find and put into practice new therapies to lower high arterial blood pressure (BP). Among these new methods of treatment, the most promising is the renal sympathetic denervation, showing positive results with the second generation devices. This review summarizes current knowledge about the treatment of RH, with an emphasis on new therapeutic strategies to achieve optimal blood pressure control.
No takes yet. Share an insight, caveat, or question.
Cherneva et al. (2020) conducted a review in Resistant hypertension. Novel therapeutic strategies (e.g., renal denervation, sacubitril/valsartan) was evaluated. Novel therapeutic strategies, including renal sympathetic denervation and sacubitril/valsartan, offer promising approaches for achieving optimal blood pressure control in patients with resistant hypertension.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: